MDT

81.04

-4.04%↓

VEEV

209.39

-4.02%↓

A

99.34

-5.12%↓

CHE

568.88

-2.66%↓

HQY

78.91

-4.65%↓

MDT

81.04

-4.04%↓

VEEV

209.39

-4.02%↓

A

99.34

-5.12%↓

CHE

568.88

-2.66%↓

HQY

78.91

-4.65%↓

MDT

81.04

-4.04%↓

VEEV

209.39

-4.02%↓

A

99.34

-5.12%↓

CHE

568.88

-2.66%↓

HQY

78.91

-4.65%↓

MDT

81.04

-4.04%↓

VEEV

209.39

-4.02%↓

A

99.34

-5.12%↓

CHE

568.88

-2.66%↓

HQY

78.91

-4.65%↓

MDT

81.04

-4.04%↓

VEEV

209.39

-4.02%↓

A

99.34

-5.12%↓

CHE

568.88

-2.66%↓

HQY

78.91

-4.65%↓

Search

Corvus Pharmaceuticals Inc

Închisă

2.78 -4.14

Rezumat

Modificarea prețului

24h

Curent

Minim

2.73

Maxim

3.03

Indicatori cheie

By Trading Economics

Venit

28M

-12M

EPS

-0.143

Angajați

31

EBITDA

-851K

-8.1M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+337.23% upside

Dividende

By Dow Jones

Următoarele câștiguri

6 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-79M

194M

Deschiderea anterioară

6.92

Închiderea anterioară

2.78

Scor tehnic

By Trading Central

Încredere

Bearish Evidence

Corvus Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

8 apr. 2025, 22:42 UTC

Principalele dinamici ale pieței

Peabody Energy Shares Climb on Trump Executive Orders Boosting Coal Industry

8 apr. 2025, 22:35 UTC

Câștiguri
Principalele dinamici ale pieței

Cal-Maine Foods Shares Fall As Justice Dept Probes Egg Prices

8 apr. 2025, 21:30 UTC

Câștiguri

Cal-Maine Foods Cooperating With Justice Dept Probe Into Egg Price Increases -- Update

8 apr. 2025, 21:21 UTC

Câștiguri

Cal-Maine Foods Cooperating With Justice Dept Probe into Egg Price Increases

9 apr. 2025, 00:00 UTC

Top știri

Trump's Tariffs Put Fed Chair Powell in a 'No-Win Situation' -- WSJ

8 apr. 2025, 23:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 apr. 2025, 23:45 UTC

Market Talk

Nikkei May Fall Amid U.S. Tariff Uncertainty -- Market Talk

8 apr. 2025, 23:43 UTC

Market Talk

Lithium Oversupply Weighs on Price Outlook -- Market Talk

8 apr. 2025, 23:43 UTC

Achiziții, Fuziuni, Preluări

Woolworths' Rivals Have Other Options to Source Ready Meals, ACCC Says

8 apr. 2025, 23:42 UTC

Market Talk

Gold Falls on Possible Unwinding of Long Positions to Raise Cash -- Market Talk

8 apr. 2025, 23:42 UTC

Achiziții, Fuziuni, Preluări

Beak & Johnston Makes Ready Meals, Pastries for Wholesale, Retail

8 apr. 2025, 23:41 UTC

Achiziții, Fuziuni, Preluări

Woolworths' Acquisition Unlikely to Have Substantial Anti-Competitive Effect, ACCC Says

8 apr. 2025, 23:40 UTC

Achiziții, Fuziuni, Preluări

Australian Competition and Consumer Commission: Will Not Oppose Transaction

8 apr. 2025, 23:39 UTC

Achiziții, Fuziuni, Preluări

Australian Competition Regulator to Allow Woolworths' Acquisition of Beak & Johnston

8 apr. 2025, 23:21 UTC

Achiziții, Fuziuni, Preluări

U.S. Steel: $75 per Shr That the Ancora 'Plan' Proposes Is Really an Unrealistic, Distant Future Value Pipedream Rooted Firmly in Fiction >X

8 apr. 2025, 23:21 UTC

Achiziții, Fuziuni, Preluări

U.S. Steel: Stockholders Should Be Very Skeptical of Ancora's 'Plan' or That Their Nominees Could or Would Vigorously Fight for the Nippon Steel Deal >X

8 apr. 2025, 21:26 UTC

Top știri

When Coffee Mate Made a 'White Lotus' Piña Colada Creamer, It Had No Idea How the Season Would End -- WSJ

8 apr. 2025, 21:26 UTC

Câștiguri

Pfizer Stock's Fall to '97 Level Lifts Yield Near 8%. Dividend Looks Safe. -- Barrons.com

8 apr. 2025, 21:18 UTC

Achiziții, Fuziuni, Preluări

Peabody Energy: Remains in Conversation With Anglo Amer to Better Understand Impacts of Event, Preserving All Rights and Protections Under Purchase Agreements >BTU

8 apr. 2025, 21:18 UTC

Achiziții, Fuziuni, Preluări

Peabody Energy: Following Ignition Event Last Week at Anglo Amer's Moranbah North Mine, Reviewing Options Related to Acquisition of Steelmaking Coal Assets From Anglo Amer >BTU

8 apr. 2025, 21:06 UTC

Top știri

Stocks Are in Turmoil, but Treasury Yields Are Stubbornly High -- Update

8 apr. 2025, 20:50 UTC

Top știri

Harley-Davidson Seeks New CEO, Facing Sales Slump and Tariffs -- 3rd Update

8 apr. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

8 apr. 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

8 apr. 2025, 20:49 UTC

Top știri

Vanguard Cuts Forecast for U.S. Economy. Tariffs Have Us 'Dancing With Recession.' -- Barrons.com

8 apr. 2025, 20:40 UTC

Câștiguri

BYD Stock Soars. It's Catching Up to Tesla in Yet Another Way. -- Barrons.com

8 apr. 2025, 20:28 UTC

Câștiguri

Sandstorm Gold: Will Release 1Q Results on May 6 After Markets Close >SSL.T

8 apr. 2025, 20:28 UTC

Câștiguri

Sandstorm Gold: During Three Mos Ended March 31, Realized Record Preliminary Revenue of $50.1M (20,316 Attributable Gold Equivalent Ounces and $42.8M in Rev for the Comparable Period in 2024) >SSL.T

8 apr. 2025, 20:28 UTC

Câștiguri

Sandstorm Gold: Record Preliminary Total Sales, Royalties, Income From Other Interests of $54.1M for Three Mos Ended March 31 ($42.8M in Total Sales, Royalties, Income From Other Interests for Comparable Period in 2024) >SSL.T

8 apr. 2025, 20:28 UTC

Câștiguri

Sandstorm Gold: During Three Mos Ended March 31, Sold Approximately 18,500 Attributable Gold Equivalent Ounces >SSL.T

Comparație

Modificare preț

Corvus Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

337.23% sus

Prognoză pe 12 luni

Medie 12.33 USD  337.23%

Maxim 15 USD

Minim 11 USD

În baza a 3 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCorvus Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

3 ratings

3

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

2.56 / 2.97Suport & Rezistență

Termen scurt

Bearish Evidence

Termen mediu

Bearish Evidence

Termen lung

Bearish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.